|
|
| Drug Name: | Hydralazine Hydrochloride |
| Manufacturer: | Par Pharmaceutical, Inc. |
| Other Info: | |
| Clinical Trials: | |
In a few patients hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis.
In such patients hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.
Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.
Long-term treatment with steroids may be necessary.
(See PRECAUTIONS,Laboratory Tests.)
NIH - Clinical Trials